Repurposing cAMP-modulating medications to promote β-cell replication

Area of Science:

• Endocrinology
• Cell Biology
• Pharmacology

Background:

• Loss of beta-cell mass is a primary characteristic of diabetes.
• Developing therapies for beta-cell regeneration is a critical research area.
• Cyclic AMP (cAMP) is a key intracellular messenger regulating beta-cell replication.

Purpose of the Study:

• To identify medications that enhance beta-cell growth by increasing cAMP stability or synthesis.
• To investigate the role of phosphodiesterase (PDE) inhibitors and adrenergic signaling in beta-cell replication.

Main Methods:

• High-content screening of a phosphodiesterase inhibitor library.
• Assessing the effects of dipyridamole and mirtazapine on beta-cell replication in vitro and in vivo.
• Investigating the mechanisms involving adenosine receptors, alpha(2)-adrenergic receptors, and catecholamine-inactivating enzymes.

Main Results:

• PDE3, -4, and -10 inhibitors, including dipyridamole, promoted beta-cell replication via adenosine receptors, specifically in beta-cells.
• Norepinephrine (NE) suppresses beta-cell replication by activating alpha(2)-adrenergic receptors, an effect dominant over PDE inhibitors.
• Mirtazapine, an alpha(2)-adrenergic receptor antagonist, prevented NE-induced suppression of beta-cell replication.
• Dipyridamole and/or mirtazapine treatment promoted beta-cell replication in mice.
• Dipyridamole treatment in humans was associated with reduced glucose levels.

Conclusions:

• This study reveals novel mechanisms of cAMP-dependent beta-cell growth regulation.
• Commonly prescribed medications like dipyridamole and mirtazapine show potential for influencing beta-cell mass and function.
• These findings offer new therapeutic strategies for diabetes by targeting beta-cell regeneration.